Related Experiment Video

Updated: Jun 25, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

[Genetic polymorphism and risk of arterial thrombosis in patients with atrial fibrillation]

E V Serdechnaia, B A Tatarskiĭ, E V Kazakevich

    Klinicheskaia Meditsina
    |February 21, 2009
    PubMed

    Insights

    Six genetic factors increase the risk of stroke in atrial fibrillation (AF) patients. Specifically, the FGB-455A gene variant, mitral regurgitation, and prolonged AF duration independently predict thromboembolic stroke.

    Area of Science:

    • Cardiovascular Genetics
    • Thrombophilia Research
    • Atrial Fibrillation Pathophysiology

    Background:

    • Atrial fibrillation (AF) is a significant risk factor for thromboembolic stroke.
    • Identifying genetic predispositions to thrombophilia is crucial for stroke risk assessment in AF patients.

    Purpose of the Study:

    • To investigate the role of genetic determinants in the risk of thromboembolic stroke among patients with atrial fibrillation.
    • To identify independent predictors of stroke in complicated AF cases.

    Main Methods:

    • Analysis of 6 genetic determinants associated with thrombophilia.
    • Comparison of allele frequencies in AF patients and control groups.
    • Statistical assessment of risk factors including FGB gene variants, mitral regurgitation, and AF duration.

    Main Results:

    • Six genetic determinants were identified as significant risk factors for thromboembolic stroke in AF patients.
    • A higher prevalence of the FGB gene's A-allele was observed in complicated AF cases compared to controls.
    • FGB-455A carriage, grade II mitral regurgitation, and AF duration exceeding 48 hours were identified as independent predictors of thromboembolic stroke.

    Conclusions:

    • Genetic factors, particularly FGB gene variants, play a crucial role in stroke risk for AF patients.
    • Clinical factors like mitral regurgitation severity and AF duration further refine stroke risk prediction.
    • These findings highlight the importance of genetic screening and comprehensive risk assessment in managing AF patients.

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

    Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

    Published on: July 20, 2022

    Related Concept Videos

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Principles of Pharmacogenetics: Types of Genetic Variants01:27

    Principles of Pharmacogenetics: Types of Genetic Variants

    The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Drug Toxicity: Risk factors01:24

    Drug Toxicity: Risk factors

    Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...